Cardiac effects of tricyclic antidepressant medication

A preliminary study of nortriptyline

D. J. E. TAYLOR AND R. A. BRAITHWAITE

From Kent and Canterbury Hospital, Canterbury; and Poisons Unit, Guy's Hospital, London

SUMMARY Systolic time intervals and drug plasma concentrations have been measured in a group of patients receiving repeated treatment with nortriptyline. Significant positive correlations between plasma nortriptyline levels and prolongation of pre-ejection phase (P < 0.005) and increase in the ratio pre-ejection phase, left ventricular ejection time (P < 0.05) were obtained. A deterioration in cardiac function, with increase in heart rate, resulting in a negative inotropic effect has been shown to occur with therapeutic doses of nortriptyline. The potential dangers of tricyclic antidepressant drugs on the heart in patients whose myocardium is already compromised or those who accumulate high plasma concentrations are emphasised.

During the past two decades the tricyclic antidepressant group of drugs has become firmly established as an effective treatment for various types of depressive illness. However, in this same period there have appeared numerous reports of cardiovascular complications following overdosage with this group of drugs (Barnes et al., 1968; Sacks et al., 1968; Crocker and Morton, 1969; Freeman et al., 1969; Noble and Matthew, 1969; Brown et al., 1971; Ruddy et al., 1972; Sedal et al., 1972; Brown et al., 1973; Roberts et al., 1973).

These complications have included sinus or supraventricular tachycardia, widening of the QRS complex, ST depression, bundle-branch block, hypotension, myocardial infarction, and heart block. Of more serious consequence, many of these changes have been observed in patients receiving only therapeutic doses of tricyclic drugs (Stoman, 1960; Kristiansen, 1961; Alexander and Ñino, 1969; Williams and Sherter, 1971; Scollins et al., 1972). Moreover, there have also been reports of an increased incidence of sudden death in elderly patients as a result of treatment with this group of drugs (Coull et al., 1970; Moir et al., 1972). In a number of these 'tricyclic deaths' necropsy has shown similar focal myocardial necrosis to that found in animals receiving prolonged noradrenaline infusions (Wexler et al., 1967), or in humans with phaeochromocytoma (Northfield, 1967).

However, the majority of these early studies have concerned single case reports; very few controlled investigations have been carried out until recently.

In a study by Freysschuss et al. (1970), the effect of nortriptyline medication on various cardiovascular parameters was investigated in a group of 40 depressed patients. These workers reported that, apart from a general increase in heart rate, in all but one patient the electrocardiogram both at rest and during exercise showed no abnormal changes during nortriptyline medication. However, there was one patient with a very high plasma nortriptyline level who produced a right bundle-branch block during an exercise test. A similar study was later carried out by Vohra et al. (1975), who investigated the electrocardiograms of a group of 32 depressed patients who were being treated with various tricyclic antidepressant drugs. In these patients a moderate increase in heart rate and a small prolongation of the PR interval was demonstrated.

In contrast to these earlier findings, Burrows et al. (1974) reported significant effect on atrioventricular conduction during therapeutic medication with nortriptyline, though His bundle electrography was used to obtain these findings. Further, in a case reported by Kantor et al. (1975), a 2:1 atrioventricular block developed in an elderly patient during treatment with imipramine which was directly related to the drug-plasma concentration, the block occurring below the atrioventricular node in the His-Purkinje system.

Using a somewhat different approach, Müller and Burkhardt (1974) investigated the effect of various tricyclic antidepressants on cardiac function using the technique of systolic time interval measurements.
changes (STI). The results of these studies were interpreted by the authors as evidence of a reduced myocardial contractility during prolonged treatment with these drugs.

It has been shown by many workers that the measurement of systolic time intervals is a reliable, repeatable, and simple noninvasive method of assessing myocardial performance; more specifically, the technique measures the contractile state of the left ventricular myocardium (Spodick and Kumar, 1968; Weissler et al., 1968; Martin et al., 1971; Carliner et al., 1974; Frei et al., 1974). This present study is a preliminary investigation into the effects of repeated therapeutic doses of nortriptyline upon myocardial function in a small group of patients using the techniques of STI measurement, with the simultaneous determination of plasma nortriptyline concentrations.

Patients and methods

**Measurement of STI Changes**

The STI values are obtained from a simultaneous fast speed recording of the electrocardiogram, phonocardiogram, and the carotid wave form. The total electromechanical ejection time (QS2) is measured from the start of the QRS complex in the electrocardiogram to the first high-frequency vibrations of the second heart sound. Left ventricular ejection (LVET) is measured from the beginning upswing to the base of the incisural trough of the carotid arterial pulse tracing. Pre-ejection phase (PEP) is obtained by subtracting the left ventricular ejection time from the total electromechanical systole (QS2 - LVET).

The STI values obtained vary with individual heart rates in a linear manner and previously published regression relations for the normal resting supine subject were used to calculate a further index PEPc (Weissler et al., 1968). Deviation from normal (expected) values of this function were calculated as the difference between observed intervals (PEP) and those predicted from the normal regression line (PEPc). The recordings of STIs for the present studies were made using a Cambridge multichannel recorder and Statham gold cell displacement transducer. These recordings were obtained at a chart speed of 100 mm/s, at which the measurements were judged accurate to 5 ms. Recordings were taken with the subjects in a resting state, supine, with the trunk, head, and neck raised to 30°, during an arrested expiration. Measurements were made over three cycles, with the final results expressed as the mean.

**Patients**

Eight patients who presented with various psychosomatic complaints were the subjects of the study. The age, sex, weight, and clinical diagnosis of these patients are shown in the Table. Before inclusion into the study patients were fully examined clinically and with chest x-rays and resting and exercise electrocardiograms before being judged free of cardiac disease.

After obtaining baseline (drug-free) measurements of the STIs for each subject, gradually increasing therapeutic doses of nortriptyline were prescribed over several weeks, with a period of at least 7 days on each dosage schedule; each patient acted as his or her own control. Further measurements were taken from each subject on a number of occasions during the nortriptyline treatment period, these being obtained at the same time of day on each occasion. No concomitant treatment was allowed for any patient during the study, so that the effects of barbiturates on the metabolism of nortriptyline could be avoided, and the patients were asked to abstain from alcohol during this period (Zirkle et al., 1959). No patient during the trial period developed any alteration of intraventricular conduction. Finally, measurements were taken one week after the cessation of nortriptyline in order to obtain a second baseline result.

**Plasma Nortriptyline Concentrations**

Heparinised venous blood samples were obtained from each subject at the same time as the measurement of STI values. The blood was centrifuged at 3000 rpm and the plasma removed and stored in fresh plastic tubes at -20°C before analysis. The estimation of plasma nortriptyline concentration was carried out in duplicate using a modification of the gas chromatographic technique of Braithwaite and Widdop (1971). The method had a lower limit...
Cardiac effects of nortriptyline

Fig. 1 Relation between daily dose and mean plasma nortriptyline levels.

Fig. 2 Relation between mean heart rate and plasma nortriptyline levels.

Fig. 3 Relation between difference in observed pre-ejection phase (PEP) and normal calculated value (PEPc) and plasma nortriptyline level.

Results

The relation between the daily dose of nortriptyline and mean steady-state plasma nortriptyline levels obtained in the 8 patients investigated is shown in Fig. 1, which shows that increased doses of nortriptyline produced expected rises in steady-state plasma nortriptyline levels. These results indicate that patients were obtaining therapeutic plasma nortriptyline concentrations during the trial.

of sensitivity of 20 ng/ml and the agreement between duplicate estimations was within 10 per cent.

Heart rate (HR)

Fig. 2 shows the relation between mean heart rate and plasma nortriptyline concentrations. It can be seen that the increase in heart rate obtained during nortriptyline medication appears not to rise with increasing drug plasma concentrations. The increase in heart rate during medication was reversible upon stopping the drug and post-dosage mean heart rate was similar to that obtained before treatment.

Pre-ejection phase (PEP-PEPc)

Fig. 3 shows the relation between the difference between observed (PEP) and predicted values (PEPc) with increasing plasma nortriptyline concentration. As can be seen from this figure, there seems to be a positive relation between deviation from normal values (that is, increase in PEP disproportionate to PEPc) and increasing antidepressant concentrations. Moreover, a linear regression analysis of change in pre-ejection phase values, \( \Delta \) (PEP-PEPc), against plasma nortriptyline levels for all the observations produced a statistically significant correlation (\( r = +0.42, n = 44, P < 0.005 \)). Fig. 3 also shows that post-dosage PEP values returned to those obtained before dosing and the effect of nortriptyline treatment on pre-ejection phase values was reversible.

Ratio PEP/LVET

Fig. 4 shows the relation between the ratio of PEP/LVET and plasma nortriptyline concentrations. As can be seen from this figure, there appears to be a clear increase in this ratio with increasing antidepressant concentrations. A linear regression analysis of change in ratio \( \left( \frac{\Delta \text{PEP}}{\text{LVET}} \right) \) against plasma nortriptyline concentrations for all observa-
primary effect appears to be related to the plasma nortriptyline concentration (Åsberg, 1974). Thus, the relation between increase in systolic time intervals (PEP and PEP/LVET) and plasma nortriptyline concentration obtained in the present study is evidence that the drug has a direct effect on the myocardium, the mechanism of which may be related to the drug's interaction with adrenergic nerve function. The findings of Burrows et al. (1974) that atrioventricular conduction was prolonged by more than 30 ms in patients with plasma nortriptyline levels above 200 ng/ml seem to be consistent with our own findings. Further, it has been reported by Åsberg (1974) that potentially dangerous side-effects of nortriptyline medication such as electrocardiographic disturbances and 'sudden falls' have always occurred on high plasma nortriptyline concentrations.

A majority of studies have now shown that high steady-state plasma nortriptyline concentrations are associated with a poor therapeutic outcome, with optimum response being obtained within an 'intermediate' plasma level range (Åsberg et al., 1971; Kragh-Sørensen et al., 1973, 1976; Ziegler et al., 1976; Montgomery et al., 1977). A therapeutic range of 50 to 150 ng/ml is now recommended for treatment with nortriptyline (Kragh-Sørensen et al., 1976). Large differences in steady-state plasma levels are routinely observed in individual patients receiving antidepressant therapy with nortriptyline, with some patients accumulating extremely high levels (Montgomery et al., 1977). The occurrence of these high, and therapeutically ineffective, nortriptyline concentrations on relatively small doses is the result of a slow hepatic clearance of the drug in some patients (Braithwaite et al., 1978).

The cardiac dangers associated with tricyclic antidepressant medication seem to be very real, particularly in those patients who accumulate very high plasma antidepressant concentrations, for example the elderly or those patients with impaired hepatic function. High plasma levels are also unnecessary as they now appear to produce a poorer antidepressant effect.

The present findings are of particular clinical interest. The persistent tachycardia and deterioration in inotropic state that might occur during tricyclic antidepressant treatment have a potential danger in those patients whose myocardium is already compromised. Further, the alteration in autonomic balance may be of special importance in those patients with ischaemic heart disease and may account for the episodes of sudden death reported (Coull et al., 1970; Moir et al., 1972).
Cardiac effects of nortriptyline

References


Requests for reprints to Dr D. J. E. Taylor, Kent and Canterbury Hospital, Canterbury CT1 3NG, Kent.